A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 87,500 shares of PRQR stock, worth $238,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,500
Previous 131,500 33.46%
Holding current value
$238,875
Previous $218,000 27.06%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.64 - $2.24 $72,160 - $98,560
-44,000 Reduced 33.46%
87,500 $159,000
Q2 2024

Aug 14, 2024

SELL
$1.65 - $2.39 $50,325 - $72,895
-30,500 Reduced 18.83%
131,500 $218,000
Q1 2024

May 15, 2024

SELL
$1.89 - $2.85 $12,663 - $19,095
-6,700 Reduced 3.97%
162,000 $370,000
Q4 2023

Feb 14, 2024

SELL
$1.15 - $2.21 $68,425 - $131,495
-59,500 Reduced 26.07%
168,700 $334,000
Q3 2023

Nov 14, 2023

SELL
$1.3 - $1.77 $302,900 - $412,410
-233,000 Reduced 50.52%
228,200 $296,000
Q2 2023

Aug 14, 2023

BUY
$1.62 - $2.32 $141,264 - $202,304
87,200 Added 23.32%
461,200 $747,000
Q1 2023

May 15, 2023

BUY
$1.99 - $3.66 $243,775 - $448,350
122,500 Added 48.71%
374,000 $796,000
Q4 2022

Feb 14, 2023

BUY
$0.8 - $3.7 $62,560 - $289,340
78,200 Added 45.12%
251,500 $930,000
Q3 2022

Nov 14, 2022

BUY
$0.74 - $0.89 $86,876 - $104,486
117,400 Added 210.02%
173,300 $129,000
Q2 2022

Aug 15, 2022

SELL
$0.56 - $1.0 $42,448 - $75,800
-75,800 Reduced 57.56%
55,900 $43,000
Q1 2022

May 16, 2022

BUY
$0.9 - $8.39 $118,530 - $1.1 Million
131,700 New
131,700 $119,000
Q4 2021

Feb 14, 2022

SELL
$6.58 - $8.44 $83,566 - $107,188
-12,700 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$5.16 - $8.47 $65,532 - $107,569
12,700 New
12,700 $106,000
Q3 2020

Nov 16, 2020

SELL
$4.79 - $6.3 $65,144 - $85,680
-13,600 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$4.5 - $6.53 $61,200 - $88,808
13,600 New
13,600 $83,000

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $195M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.